Asia Pacific Pulmonary Function Testing Systems Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Cart-Based PFT Systems and Stationery PFT Systems), Test Type (Spirometry, Lung Volume, Gas Exchange Testing, Maximum Voluntary Ventilation, Oxygen Titration Test, and Others), Component (Hardware, Software, and Services), Application (Chronic Obstructive Pulmonary Disorder, Asthma, Chronic Shortness of Breath, Restrictive Lung Disease, and Others), and End User (Hospitals, Specialty Clinics, and Diagnostic Laboratories)

The Asia Pacific pulmonary function testing systems market was valued at US$  58.00 million in 2022 and is expected to reach US$ 87.40 million by 2028; it is estimated to register a CAGR of 7.1% from 2022 to 2028.

Home Healthcare Pulmonary Function Testing Systems to Provide Lucrative Opportunity for Asia Pacific Pulmonary Function Testing Systems Market Growth in Coming Years

The majority of lung function tests require specialized equipment that is only available in medical settings. However, at-home spirometers are available for patients suffering from lung disease. New approaches have enabled at-home spirometry to be performed with the assistance of a tablet or smartphone. Various leading companies are launching innovative medical products, particularly to perform sophisticated lung assessments at patients' homes. Moreover, EasyOne Pro provides accurate results through reliable ultrasound technology by eliminating calibration and maintenance costs. Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) testing can determine shortness of breath caused due to respiratory or cardiac disease and differentiate between asthma and chronic obstructive pulmonary disorder (COPD) for appropriate treatment. Therefore, commercializing home healthcare pulmonary function testing systems products is likely to offer lucrative opportunities for the growth of the Asia Pacific pulmonary function testing systems market in the coming years.

Asia Pacific Pulmonary Function Testing Systems Market Overview

The pulmonary function testing systems market growth in Asia Pacific countries is attributed to growing awareness regarding the usage of pulmonary function tests and a high emphasis on enhancing hospital infrastructure. Moreover, the presence of top competitive players in developing countries of Asia Pacific is expected to propel the overall market growth during the forecast period.

Asia Pacific Pulmonary Function Testing Systems Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Pulmonary Function Testing Systems Market Segmentation

The Asia Pacific pulmonary function testing systems market is segmented on the basis of type, test type, component, application, end user, and country.

Based on type, the Asia Pacific pulmonary function testing systems market is bifurcated into cart-based PFT systems and stationery PFT systems. The cart-based PFT systems segment held a larger share of the Asia Pacific pulmonary function testing systems market in 2022.

Based on test type, the Asia Pacific pulmonary function testing systems market is segmented into spirometry, lung volume, gas exchange testing, maximum voluntary ventilation, oxygen titration test, and others. The spirometry segment held the largest share of the Asia Pacific pulmonary function testing systems market in 2022.

Based on component, the Asia Pacific pulmonary function testing systems market is segmented into hardware, software, and services. The hardware segment held the largest share of the Asia Pacific pulmonary function testing systems market in 2022.

Based on application, the Asia Pacific pulmonary function testing systems market is segmented into chronic obstructive pulmonary disorder, asthma, chronic shortness of breath, restrictive lung disease, and others. The chronic obstructive pulmonary disorder segment held the largest share of the Asia Pacific pulmonary function testing systems market in 2022.

Based on end-user, the Asia Pacific pulmonary function testing systems market is segmented into hospitals, specialty clinics, and diagnostic laboratories. The hospitals segment held the largest share of the Asia Pacific pulmonary function testing systems market in 2022.

Based on country, the Asia Pacific pulmonary function testing systems market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the share of the Asia Pacific pulmonary function testing systems market in 2022.   

COSMED Srl, KoKo PFT Ltd, MGC Diagnostics Corp, ndd Medical Technologies Inc, PulmOne Advanced Medical Devices Ltd, Schiller AG, and Vyaire Medical Inc are the leading companies operating in the Asia Pacific pulmonary function testing systems market.    

1. Chest MI Inc
2. COSMED Srl
3. MGC Diagnostics Corp
4. Minato Medical Science Co Ltd
5. PulmOne Advanced Medical Devices Ltd
6. Schiller AG
7. Vyaire Medical Inc

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pulmonary function testing systems market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific pulmonary function testing systems market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.